Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

AIMS/HYPOTHESIS: The sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin slows progression of kidney function decline in type 2 diabetes. The aim of this study was to assess the effect of the SGLT2 inhibitor canagliflozin on biomarkers for progression of diabetic kidney disease (DKD). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Heerspink, Hiddo J. L., Perco, Paul, Mulder, Skander, Leierer, Johannes, Hansen, Michael K., Heinzel, Andreas, Mayer, Gert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560022/
https://www.ncbi.nlm.nih.gov/pubmed/31001673
http://dx.doi.org/10.1007/s00125-019-4859-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560022/
https://www.ncbi.nlm.nih.gov/pubmed/31001673
http://dx.doi.org/10.1007/s00125-019-4859-4

Ejemplares similares